Recently funded projects:
Peptidase-Antibody – Programm zur Förderung von Forschung, Innovation und Technologien (ProFIT Brandenburg), Nr. 8016982, 8016983
The main goal of the project is the development and characterization of the novel peptidase inhibitor Procizumab. Within the scope of the project, we develop a GMP cell line of Procizumab and characterize the antibody with different preclinical and biochemical methods. In addition, we develop immunoassays to detect the peptidase and Procizumab in plasma samples.